Abiopharma

🔍 Schneider Jennifer (Director)

Company: VERTEX PHARMACEUTICALS INC / MA (VRTX)

Report Date: 2026-05-01

Detailed Transactions and Holdings:

• Acquired 472 shares of Common Stock (Direct)
  Date: 2026-05-01 | Code: A | equity_swap_involved: 0 | shares_owned_after: 2,190.00 | transaction_form_type: 4 | Footnotes: F1
• Sold 796 shares of Common Stock (Direct)
  Date: 2026-05-01 | Code: D | equity_swap_involved: 0 | shares_owned_after: 1,394.00 | transaction_form_type: 4 | Footnotes: F2
• Acquired 1,433 shares of Stock Option (Right to Buy) at $424.45 per share (Derivative)
  Date: 2026-05-01 | Code: A | Expires: 2036-04-30 | equity_swap_involved: 0 | shares_owned_after: 1,433.00 | transaction_form_type: 4 | Footnotes: F3
• Acquired 796 shares of Deferred Stock Units (Derivative)
  Date: 2026-05-01 | Code: A | equity_swap_involved: 0 | shares_owned_after: 796.00 | transaction_form_type: 4 | Footnotes: F4, F2, F4, F4

Footnotes:

• F1: Restricted stock unit award that vests, subject to certain limited exceptions, on the first anniversary of the grant date.
• F2: Upon the vesting of restricted stock units granted to Dr. Schneider on May 1, 2025, Dr. Schneider deferred the receipt of 796 shares of common stock and received instead 796 deferred stock units pursuant to our deferred compensation plan. As a result, Dr. Schneider is reporting the disposition of 796 shares of common stock in exchange for an equal number of deferred stock units.
• F3: Fully vested.
• F4: Each deferred stock unit represents one share of common stock and is paid out in common stock upon the earliest to occur of (i) termination of Dr. Schneider's service on our board of directors, (ii) a change of control of our company and (iii) Dr. Schneider's disability or death.